Janssen looks to turn PhI­II win for Ry­bre­vant in EGFR-mu­tat­ed NSCLC in­to pres­sure on As­traZeneca block­buster

John­son & John­son’s Janssen said Wednes­day that its bis­pe­cif­ic an­ti­body Ry­bre­vant (ami­van­tam­ab-vmjw) in com­bo with laz­er­tinib met its dual pri­ma­ry end­points in a Phase III tri­al for pa­tients with a type of non-small cell lung can­cer.

The com­pa­ny tout­ed the re­sults as the first to show a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in pro­gres­sion-free sur­vival in the post-Tagris­so (os­imer­tinib) set­ting. Janssen is look­ing to win over a chunk of the mar­ket cur­rent­ly held by As­traZeneca’s block­buster Tagris­so, which is the first-line treat­ment for this set­ting, and gen­er­at­ed sales of $5.4 bil­lion in 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.